skip to main content

Pancreatic Cancer

Research suggests a high fat diet and endurance enhancers linked to pancreatic cancer

A study published in Nature Communications, led by Imad Shureiqi, M.D., shows that, pre-cancerous pancreatic lesions in mice, similar to those found in humans, contain higher levels of the transcriptional receptor peroxisome proliferator activated receptor-delta (PPARδ).

Pancreatic cancer cells feed off hyaluronic acid

Hyaluronic acid, or HA, is a known presence in pancreatic tumors, but a new study from researchers at Rogel Cancer Center shows that hyaluronic acid also acts as food to the cancer cells. These findings, recently published in eLife, provide insight into how pancreatic cancer cells grow and indicate new possibilities to treat them.

A new strategy for killing pancreatic cancer cells is through a type of cell death known as ferroptosis

A new study led by the University of Michigan Rogel Cancer Center demonstrates how inhibiting a key enzyme known as GOT1 can flip a switch in the cancer cells — causing them to shift from using nutrients to fuel growth toward conserving them to maintain energy levels.

Protein ApoE is a Factor in Growth of Pancreatic Cancer Cells

ApoE, an apolipoprotein known to play roles in cardiovascular disease and Alzheimer’s, is elevated in the blood of people with pancreatic adenocarcinoma, according to this new research.

The best way to treat pancreatic cancer may be starve the cancer cells

A University of Michigan-led study is shedding new light on the way pancreatic cancer cells turn nearby connective tissue cells into co-conspirators in their deadly growth. The findings also suggest a new potential strategy against pancreatic cancer by identifying critical components of metabolic cross talk between cells that might be attacked with new therapies, starving the cancer cells of vital nutrients.

Researchers find a protein which may trigger the development of pancreatic cancer

Researchers at the University of Michigan Rogel Cancer Center have identified a protein -- Argonaute 2 -- that appears to be critical for the progression of benign precursor lesions into pancreatic cancer. Argonaute 2 interacts with K-RAS, which helps relay signals from the outside of a cell to its nucleus. Mutations in the KRAS gene drive more than 90% of pancreatic cancers, and currently there are no therapies that target these mutations.

Starving Pancreatic Cancer of Cysteine Kills Tumor Cells, Collaborative Study Finds

A new, collaborative study between the Rogel Cancer Center and researchers from the Columbia University Irving Medical Center and the Herbert Irving Comprehensive Cancer Center suggests a compound in development for a rare kidney stone disease may have potential against pancreatic cancer.

Improving Outcomes for Patients with Pancreatic Cancer

While researchers at the U-M Rogel Cancer Center and elsewhere continue to pursue scientific insights into pancreatic cancer and develop new therapeutic approaches, surgeons on the front line of patient care are also working hard to improve outcomes.

New Treatment Combination for Pancreatic Cancer Shows Promising Results

A clinical trial testing a new pancreatic cancer drug had promising initial results, say University of Michigan Rogel Cancer Center researchers in the Journal of Clinical Oncology. Investigators ran a phase 1 clinical trial that looked at AZD1775, an inhibitor designed to block an enzyme called Wee1, which plays a role in repairing damaged DNA. The trial builds on almost 20 years of research at U-M focused on improving the treatment of pancreatic cancer cases that are too advanced for surgery.